HEMEX is a proud partner of the European Consortium, that was awarded €4.5 million by the European Union for the ELR-SCAR project to validate a novel hydrogel biomaterial for prevention of scar tissue forming in the heart following a heart attack. This project will transform and fundamentally improve clinical practice in this crucial field of cardiology, resulting in a reduction of the enormous burden that MI and its leading cause, IHD, places on society as a whole and on the individual patient.
More info @University of Galway
About HEMEX
HEMEX is a CRO providing clinical services to European biotech and medtech companies, assisting them throughout the clinical development process to ensure that products reach the market swiftly. Located in the Basel region, a major life sciences hub, and with offices in Germany, Benelux, and the United States, we are well positioned to serve small and medium enterprises (SMEs) with multinational clinical projects. The comprehensive package of services we provide includes clinical operations, quality management, regulatory guidance, grant writing services, and fundraising options. At HEMEX, we guarantee fast and clear communication, local accessibility, and transparency to meet the objectives of our clients. For more information, visit https://hemex.ch/